Endogenous PGE2 induces MCP-1 expression via EP4/p38 MAPK signaling in melanoma

Oncology Letters

Volumn 5, Issue 2, 2013, Pages 645-650

  Tang, Mingrui ^a   Wang, Yuxin ^a   Han, Sihuan ^a   Guo, Shu ^a   Xu, Nan ^a   Guo, Jiayan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2; Macrophage chemoattractant protein 1; Prostaglandin E2

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL) IMIDAZOLE; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; CYCLOOXYGENASE 2; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL) METHANESULFONAMIDE; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MACROPHAGE MIGRATION; MELANOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 84871605355     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1047     Document Type: Article

References (32)

1. Thun MJ, Namboodiri MM and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596, 1991.
2. Kawamori T, Rao CV, Seibert K and Reddy BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58: 409-412, 1998.
3. Harris RE, Alshafie GA, Abou-Issa H and Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 60: 2101-2103, 2000.
4. Half E, Tang XM, Gwyn K, Sahin A, Wathen K and SinicropeFA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma insitu. CancerRes 62: 1676-1681, 2002.
5. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, NakamuraS, Ogawa M, Mitsudomi T, Sugiura T and TakahashiT: Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58: 3761-3764, 1998.
6. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, NouraS, Oshima S, Nagano H, Dono K, Umeshita K, IshikawaO, et al: Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 5: 2018-2024, 1999.
7. Oshima H, Oshima M, Inaba K and Taketo MM: Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J 23: 1669-1678, 2004.
8. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M and Dubinett SM: Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. CancerRes 65: 6275-6281, 2005.
9. Han C and Wu T: Cyclooxygenase-2-derived prostaglandinE2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 280: 24053-24063, 2005.
10. Buchanan FG, Wang D, Bargiacchi F and DuBois RN: Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278: 35451-35457, 2003.
11. Chang SH, Liu CH, Conway R, Han DK, NithipatikomK, TrifanOC, Lane TF and Hla T: Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101: 591-596, 2004.
12. Denkert C, Köbel M, Berger S, Siegert A, Leclere A, Trefzer U and Hauptmann S: Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 61: 303-308, 2001.
13. Singh T and Katiyar SK: Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition. PLoS One6: e25224, 2011.
14. Vaid M, Singh T and Katiyar SK: Grape seed proanthocyanidins inhibit melanoma cell invasiveness by reduction of PGE2 synthesis and reversal of epithelial-to-mesenchymal transition. PLoS One 6: e21539, 2011.
15. Singh T, Vaid M, Katiyar N, Sharma S and Katiyar SK: Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E2 and prostaglandin E2 receptors. Carcinogenesis32: 86-92, 2011.
16. Torisu H, Ono M, Kiryu H, Furue M, Ohmoto Y, NakayamaJ, Nishioka Y, Sone S and Kuwano M: Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer 85: 182-188, 2000.
17. Varney ML, Johansson SL and Singh RK: Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignantmelanoma: role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. Melanoma Res 15: 417-425, 2005.
18. Nakasone Y, Fujimoto M, Matsushita T, Hamaguchi Y, Huu DL, Yanaba M, Sato S, Takehara K and Hasegawa M: Host-derived MCP-1 and MIP-1α regulate protective anti-tumor immunity to localized and metastatic B16 melanoma. Am J Pathol 180: 365-374, 2012.
19. Oshima H, Hioki K, Popivanova BK, Oguma K, Van RooijenN, Ishikawa TO and Oshima M: Prostaglandin E2 signaling and bacterial infection recruit tumor-promoting macrophages to mouse gastric tumors. Gastroenterology 140: 596-607. e7, 2011.
20. Siegle I, Klein T, Backman JT, Saal JG, Nüsing RM and Fritz P: Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum 41: 122-129, 1998.
21. Ratcliffe MJ, Walding A, Shelton PA, Flaherty A and DougallIG: Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-alpha release from human alveolarmacrophages. Eur Respir J 29: 986-994, 2007.
22. Fennekohl A, Sugimoto Y, Segi E, Maruyama T, Ichikawa A and Püschel GP: Contribution of the two Gs-coupled PGE2-receptors EP2-receptor and EP4-receptor to the inhibition by PGE2 of the LPS-induced TNFalpha-formation in Kupffer cells from EP2-or EP4-receptor-deficient mice. Pivotal role for the EP4-receptor in wild type Kupffer cells. J Hepatol 36: 328-334, 2002.
23. Wang MT, Honn KV and Nie D: Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 26: 525-534, 2007.
24. Fujita M, Kohanbash G, Fellows-Mayle W, Hamilton RL, Komohara Y, Decker SA, Ohlfest JR and Okada H: COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 71: 2664-2674, 2011.
25. Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA, Qualtrough D, Williams AC and Paraskeva C: Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 66: 3106-3113, 2006.
26. Zhang Y and Daaka Y: PGE2 promotes angiogenesis through EP4 and PKA Cγ pathway. Blood 118: 5355-5364, 2011.
27. Timoshenko AV, Xu G, Chakrabarti S, Lala PK and ChakrabortyC: Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 289: 265-274, 2003.
28. Sheng H, Shao J, Washington MK and DuBois RN: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. JBiol Chem 276: 18075-18081, 2001.
29. Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, Breyer RM, Morrow JD and Capdevila JH: Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 279: 29797-29804, 2004.
30. Conti I and Rollins BJ: CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 14: 149-154, 2004.
31. + T-cell recruitment. Cancer Res 69: 3077-3085, 2009.
32. Zhang T, Somasundaram R, Berencsi K, Caputo L, GimottyP, Rani P, Guerry D, Swoboda R and Herlyn D: Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. EurJ Immunol 36: 457-467, 2006.